To evaluate CBS and rpL3 clinical significance in lung cancer, we employed quantitative real-time PCR (qRT-PCR) and immunoblotting to assess the expression of CBS and rpL3 at the mRNA and protein levels in 21 lung cancers and normal tissues. Here, CBS is linked to lung carcinoma.